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Available online 13 April 20178-Oxoguanine, a common mutagenic DNA lesion, generates G:CNT:A transversions via mispairing with adenine
during DNA replication. When operating normally, the MUTYH DNA glycosylase prevents 8-oxoguanine-related
mutagenesis by excising the incorporated adenine. BiallelicMUTYHmutations impair this enzymatic function and
are associated with colorectal cancer (CRC) inMUTYH-Associated Polyposis (MAP) syndrome. Here, we perform
whole-exome sequencing that reveals amodestmutator phenotype inMAPCRCs compared to sporadic CRC stem
cell lines or bulk tumours. The excess G:CNT:A transversion mutations in MAP CRCs exhibits a novel mutational
signature, termed Signature 36, with a strong sequence dependence. TheMUTYHmutational signature reflecting
persistent 8-oxoG:A mismatches occurs frequently in the APC, KRAS, PIK3CA, FAT4, TP53, FAT1, AMER1, KDM6A,
SMAD4 and SMAD2 genes that are associated with CRC. The occurrence of Signature 36 in other types of
human cancer indicates that DNA 8-oxoguanine-relatedmutations might contribute to the development of can-
cer in other organs.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
MUTYH-associated polyposis
Colorectal cancer
8-Oxoguanine
Base excision repair
Exome sequencing
Mutational signatureignami).
. This is an open access article under1. Introduction
DNA repair provides amajor protection against cancer, and germline
DNA repair defects in inherited syndromes confer a significant cancer
predisposition. DNA replication errors are a major source of mutations,
and early-onset colorectal and other cancers are associated with
germline mutations in DNA mismatch repair (MMR) genes (Lynch
et al., 2015) or in the proofreading exonuclease domains of DNAthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tionalmechanism, endogenously or exogenously generated reactive ox-
ygen species (ROS) induce pre-mutagenic DNA lesions. Most ROS-
induced base damage is repaired by base excision repair (BER) initiated
by DNA glycosylases. 8-Oxoguanine (8-oxoG), one of themost common
oxidative DNA lesions canmispair with adenine during DNA replication
to generate G:CNT:A transversion mutations. 8-oxoG-induced muta-
genesis is prevented by the cooperative action of the DNA glycosylases
encoded by the OGG1 and MUTYH genes. OGG1 removes 8-oxoG from
8-oxoG:C pairs and MUTYH scans the newly-synthesized daughter
strand to locate and remove incorporated adenine mispaired with 8-
oxoG (Mazzei et al., 2013; Markkanen et al., 2013; Tsuzuki et al.,
2007). A hydrolase encoded by the MTH1 gene provides a third level
of protection against oxidative mutagenesis by degrading 8-oxodGTP
to prevent the incorporation of 8-oxodGMP into DNA (Mo et al.,
1992). Inactivation of any of these genes increases steady-state DNA
8-oxoG levels and confers a mutator phenotype (Klungland et al.,
1999; Tsuzuki et al., 2001; Hirano et al., 2003).
To date, no human disease has been associated with defective OGG1
or MTH1 activities. In contrast, germline biallelicMUTYHmutations un-
derlieMUTYH-associated polyposis (MAP), a recessively heritable colo-
rectal polyposis with a predisposition to colorectal cancer (CRC)
(Al-Tassan et al., 2002; Sieber et al., 2003). CRCs in MAP patients bear
distinctive somatic G:CNT:A transversions in the APC gene (Al-Tassan
et al., 2002; Sieber et al., 2003; Jones et al., 2002). The relationship be-
tween defective repair of oxidized DNA and CRC susceptibility was
strengthened by the recent report that germline mutations in NTHL1,
encoding a DNA glycosylase involved in the BER of oxidized pyrimidines
are associated with a polyposis clinically similar to MAP (Weren et al.,
2015). Thus, two repair pathways counteract CRC susceptibility by
acting at replication to process mismatches containing oxidized
DNA bases.
Mutational signatures in cancer genomes provide indications of the
mechanisms underlying neoplastic transformation (Alexandrov, 2015;
Alexandrov et al., 2013a,b, 2015; Helleday et al., 2014). Thus, CRC
fromMAP patients offer the unique opportunity to identify amutational
fingerprint of persistent 8-oxoG:A mismatches. Here, we report that
whole-exome DNA sequencing identifies a distinct mutational signa-
ture of G:CNT:A transversions in MAP CRC. The mutational signature
is reflected in the specific pattern of oncogenes/tumour suppressors in-
volved in colorectal carcinogenesis and associated with inactive
MUTYH. Our findings also indicate the possible involvement of DNA ox-
idation-relatedmutations in other types of human cancer as theMUTYH
mutational fingerprint is present in cancers of other organs.2. Material and Methods
2.1. Subjects and Tissue Samples
All subjects included in this study gave informed consent for gene
testing and related research (Table S1). The local scientific IRB approved
the collection and usage of tumour samples for this research (CRO
Aviano IRB-03-2016). Blood, normal intestinal mucosa, adenomas and
CRCs were retrospectively obtained fromMAP patients with confirmed
constitutional biallelicmutations in theMUTYH gene. CRCswere collect-
ed at surgery, while adenomas and normal mucosa were harvested at
colectomy or endoscopic polypectomy. In all cases histopathological
evaluation was performed by a pathologist.
DNA from frozen tissues was extracted using the Qiagen DNeasy Tis-
sue kit (Qiagen, Hilden, Germany) with a protocol including RNase
treatment. FFPE tissues were deparaffinized by two washes in Noxyl
(15min at 56 °C) andDNAwas then obtained using the FFPEQiagen Tis-
sue kit (Qiagen). DNA quality and concentrations were assessed using
Nanodrop spectrophotometer (ThermoFischer Scientific, MA, USA)
and Qubit Fluorometer (Invitrogen, CA, USA).2.2. Whole Exome Sequencing, Data Analysis and Validation
Whole Exome Sequencing was performed by the Beijing Genomics
Institute (BGI, Hong Kong). Target enrichment was performed using
in-solution technology (NimbleGen SeqCap EZ Library v.3.0, Roche)
and the resulting target libraries were sequenced by Illumina sequenc-
ing technology (HiSeq2000) (Illumina, San Diego, CA, USA). Raw
image files were processed by Illumina base calling software (CASAVA
1.7) using default parameters. Paired-end reads were aligned to the
human genome (UCSCGRCh37/hg19)with theBurrows-Wheeler align-
er (BWA v. 0.7.10). Presumed PCR duplicates were removed using
Picard's MarkDuplicates. The Genome Analysis Toolkit (GATK 3.2) was
used for realignment of sequences encompassing indels and for base
quality recalibration. Somatic single-nucleotide variants were detected
usingmuTect software v.1.1.6, and small indels were identified through
a comparison between indels called in individual CRCs and their
matched non-tumoural samples bymeans of the GATKHaplotype Caller
algorithm, applying the following quality filters: quality score N 100 and
quality-by-depth score N 1.5; indels below these thresholds or resulting
from four or more reads having ambiguous mapping (this number
being N10% of all aligned reads) were discarded. The resulting SNVs
and small indels were annotated by SnpEff v3.6 and dbNSFP2.8 in
terms of functional impact of variants (missense or nonsense, coding
or non-coding, locationwith respect to exon-intron junction, depth, ref-
erence/variant reads ratio, dbSNP ID, amino acid change and position,
cancer association data and structural/functional impact). Variant
validation and genotyping were performed by Sanger sequencing.
Amplicons were directly sequenced using the ABI BigDye Terminator
Sequencing kit (Applied Biosystems, Foster City, CA, USA) and an auto-
mated capillary sequencer (ABI 3500, Applied Biosystems). Sequence
electropherograms were analyzed using Sequencing Analysis Software
v.5.4 (Applied Biosystems).
2.3. Microsatellite Instability Analysis
Five mononucleotide and two pentanucleotide markers were co-
amplified using the MSI analysis system (Promega Madison, WI, USA)
according to the manufacturer's protocol. The fluorescent-labeled PCR
products obtained from constitutional DNA and tumour DNAwere sep-
arated by capillary electrophoresis using an AB3130 xl sequencer and
evaluated with the GeneMapper software (Applied Biosystems/Life
technologies). The 5 quasi-monomorphic mononucleotide markers in-
cluded in the kit have high sensitivity and specificity in detecting alter-
ations in tumour samples with mismatch repair defects. Criteria for
definition of MSS and MSI are according to the Bethesda guidelines
(Umar et al., 2004).
2.4. Mutational Signature Analysis
Prior to performing mutational signatures analysis, the mutational
catalogues of all examined samples were generated. These catalogues
include the six types of substitutions (CNA, CNG, CNT, TNA, TNC, TNG;
mutations are referred to by the pyrimidine of the mutated Watson–
Crick base pair) as well as the base immediately 5′ and the base imme-
diately 3′ of each somatic mutation. The immediate 5′ and 3′ sequence
context for each somatic mutation was extracted using the ENSEMBL
Core APIs for human genome build GRCh37.
Mutational signatures analysis was performed based on somatic
substitutions and their immediate sequence context. Briefly, mutational
signatures were deciphered for all cancer types together using our
previously developed computational MATLAB framework (Alexandrov
et al., 2013a).
The computational framework for deciphering mutational signa-
tures is freely available and it can be downloaded from: http://www.
mathworks.com/matlabcentral/fileexchange/38724. The algorithm de-
ciphers theminimal set ofmutational signatures that optimally explains
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estimates the contribution of each signature to each mutational cata-
logue. Overall, we identified multiple distinct mutational signatures,
most of which were previously reported by others or us (Alexandrov
et al., 2013a,b; Schulze et al., 2015). The names of mutational signatures
used in this manuscript are consistent with the ones on the COSMIC
website, http://cancer.sanger.ac.uk/cosmic/signatures.
2.5. Target Re-sequencing
A TruSeq Custom Amplicon (TSCA) workflow was applied for inter-
rogating targeted regions of interest in a series of MAP tumours. The
custom panel included all exons and ±10 padding intronic regions of
the following target genes: AMER1, APC, FAT1, FAT4, KDM6A, KRAS,
PIK3CA, SMAD2, SMAD4, TP53. A project of 632 amplicons having a me-
dian size of 175 bp was constructed and optimized using Design Studio
tool (Illumina). These amplicons covered a cumulative target of
60,174 bp and, according to the design, there were only 13 gaps, with
a predicted 97% in silico-coverage of the region of interest. Double
stranded DNA (250 ng) from frozen tissues and DNA from FFPE tissues
(250–500 ng) were used for library preparation according to the TSCA
protocol (Illumina). After normalization, three pooled quantified librar-
ies were sequenced on theMiSeq platform (Illumina) using the 2 × 175
configuration and run on a MiSeq Reagent kit V3 sequencing flow cell
with 175-cycle paired-end run plus two eight-cycle index reads. Data
were automatically aligned using the MiSeq Reporter and visualized
using Illumina Amplicon Viewer (Illumina) and Integrative Genomics
Viewer 2.3 (Broad Institute, Boston, U.S.A.). The vcf files were imported
into Illumina VariantStudio v2.2 software and analyzed with the default
setting. SNV and in/del variants were annotated using different filtering
options. Briefly, a) variant call quality was based on the selection of the
“PASS” filter; b) to narrow results to the somatic events, annotation of
the vast majority of constitutional variants was avoided by filtering
only variantswith globalMinor Allele Frequency b 1 and discarding var-
iants recurrent in more tumour tissues of the same individual; c) fre-
quency of the alternative allele was set at a threshold of 5%; d) the
“consequence” option was used to filter data by variants that alter the
coding potential of the transcript, i.e. frameshift, stop gained, initiator
codon, inframe insertion or deletion, splice and missense with deleteri-
ous (SIFT) or damaging (Polyphen) prediction; synonymous, intronic,
5′- and 3′- UTR and missense variants with tolerated (SIFT) and benign
(Polyphen) prediction were filtered out, unless they were reported in
the Catalogue of somatic mutations in cancer (Cosmic) database
(http://cancer.sanger.ac.uk/cosmic).
2.6. MUTYH Glycosylase Assays
Two DNA duplexes, each containing a single 8-oxodG:A mismatch
with different flanking sequences, were used as substrates for adenine
DNA glycosylase assays. HPLC-purified 30-mer oligonucleotides (5′-
CTT GCC TAC GCC ACA AGC TCC AAC TAC CAC and 5′-CTT GCC TAC
GCCAACAGC TCC AACTAC CAC), 3′-end labeledwith 6-carboxyfluores-
cein (6-FAM) were annealed to the complementary strands containing
a single 8-oxodG (at 16 nt and 17 nt from their 5’end.) All oligonucleo-
tides were from Thermo Fisher Scientific (Thermo Fisher Scientific
GmbH, Ulm, Germany). To obtain human purified MUTYH, Escherichia
coli strain BL21 CodonPlus (DE3) RIPL (Stratagene, La Jolla, CA, USA)
competent cells were transformed with a pMAL-c4E vector containing
theMUTYH-cDNA. Bacteria were grown at 37 °C in Luria Broth medium
with 5 g/l of glucose until OD 600 nm = 0.6 and then induced with
0.4 mM isopropyl-β-D-thiogalactopyranoside (IPTG) for 3 h at 25 °C.
Cells were harvested and resuspended in phosphate-buffered saline
(PBS) (1/40th of culture volume). In all, 5 mM dithiothreitol (DTT),
1 mg/ml of lysozyme and protease inhibitors (Roche) were added to
the cell suspension and incubated for 30 min on ice. Lysates were
cleared by centrifugation and the supernatant loaded on an amylosecolumn (New England BioLabs Inc., Ipswich, MA). The maltose binding
protein (MBP)-MUTYH fusion protein was eluted in 10 mM Tris–HCl,
pH 7.5, 10 mM maltose buffer. Protein containing fractions were ana-
lyzed by sodium dodecyl sulphate–polyacrylamide gel electrophoresis
(SDS–PAGE) and stained with Comassie blue dye. Protein recovery
was evaluated by gel analysis by ImageJ software, available free online
at the NIH website (http://rsb.info.nih.gov/). MUTYH active fraction
was evaluated as described before (Turco et al., 2013). In single-turn-
over conditions ([MUTYH]»[DNA]), DNA substrate (10 nM) was reacted
with an active protein (20 nM). Aliquots were withdrawn at different
times, ranging from30s to 10min, and reactionwas stoppedby addition
of NaOH (80 mM) and heating at 90 °C for 4 min. Reaction products
were separated by denaturing PAGE. Gel images were acquired by Ty-
phoon 9600 scanner (GE Healthcare, Uppsala, Sweden) and analysis
performed by Image J and Kaleidagraph software (Synergy software).
2.7. Statistical Analysis
The mutation profiles were analyzed by means of principal Compo-
nent Analysis of thematrix having as statistical units the different types
of mutations and as variables the samples.
3. Results
3.1. Determination of Somatic Mutation Frequencies by Exome Sequencing
in MAP CRC
Whole-exome DNA sequencing was performed on seven matched
CRC/normal mucosa pairs from six unrelated MAP patients. These indi-
viduals harbour either the p.Gly396Asp and p.Tyr179Cys variants that
are common among Caucasians or the p.Arg245His, p.Gly264Trpfs*7
and p.Glu480del that occur relatively frequently in ItalianMAP patients
(Aretz et al., 2014). A summary of the constitutionalMUTYH genotypes,
clinical phenotypes and pathology reports is listed in Table S1. The age
of cancer diagnosis in these MAP patients is quite ample with a range
of 27–73 years, in accordance with a recent Italian survey (Ricci et al.,
2017). All these variants compromise MUTYH activity and are associat-
ed with increased steady-state levels of DNA 8-oxoG in lymphoblastoid
cell lines (Molatore et al., 2010; D'Agostino et al., 2010; Ruggieri et al.,
2013; Grasso et al., 2014).
The number of somatic non-synonymous single nucleotide variants
(SNVs) and small insertions/deletions (indels) was similar among
MAP CRCs, with a median value of 340 mutations per sample (range:
247–423). The mutational landscape of MAP tumours was compared
to a set of 23 well-characterized colorectal cancer stem cell lines
(CSCs) previously shown to faithfully reproduce the genomic complex-
ity of CRC (De Angelis et al., 2016). As expected, the number of muta-
tions in these CSCs was dependent on MMR status, with median
values of 210 and 2215 mutations/exome in MMR-proficient (MSS)
and MMR–deficient (MSI) CSCs, respectively. These values correspond
to 3.5± 0.3 and 34.6± 6.9mutations per Mb forMSS andMSI CSCs, re-
spectively (Fig. 1A and B) and are in good agreementwith those report-
ed by The Cancer Genome Atlas Network (2012). MAP tumours
contained 5.3 ± 0.38 mutations per Mb, an increase of 1.5-fold over
the frequency in MMR-proficient CSCs (Fig. 1A). Approximate values
for mutation rates were derived by dividing the number of somatic mu-
tations per tumour by the age of the patient at diagnosis (Tomasetti
et al., 2015). Median ages of cancer diagnosis were 47 in MAP patients
and 73 years for CSCs (range: 27–73 and 47–88 years, respectively).
The mutation rate in MAP CRCs (6.8 ± 0.6) was 2-fold higher than
that inMSS CSCs (3.3± 0.3) (p-value=2.4 × 10−5; Fig. 1C). In contrast
MSI CSCs were characterized by an extreme value of 31.7 ± 6 with an
almost 10-fold increase over MSS CSCs (data not shown).
The higher frequency of mutations in MAP tumours was driven
predominantly by an increase in SNVs and the number of indels was
relatively low compared to either MSS or MSI CSCs (Fig. 1D). MSI is
Fig. 1. Somaticmutation frequencies inMAP CRCs and colorectal CSCs. a) and b)Mutation frequencies perMb inMAP CRCs (red), andMSS (blue) andMSI CSCs (purple). c)Mutation rates
inMAPCRCs andMSS CSCs calculated bydividing thenumber of somaticmutationsper tumour by the age of thepatient at diagnosis. d)Distribution of indels (grey) andSNVs inMAPCRCs
(red), and MSS (blue) and MSI (purple) CSCs. Data are mean ± SE.
42 A. Viel et al. / EBioMedicine 20 (2017) 39–49not a characteristic of MAP CRCs and there were no detectable
alterations of microsatellite markers (NR21, BAT-26, BAT-25, NR-24,
MONO-27) (Fig. S1).Fig. 2. Mutational spectra in MAP CRCs and colorectal CSCs. a) Mutational spectrum for ba
transversions in MAP CRCs (red), MSS CSCs (blue) and MSI CSCs (purple). Data are mean ± S
MSI CSCs with P values b 0.001 (Student's t-test).MAP CRCs exhibited a homogeneous mutational spectrum in the
seven patients, whichwas characterized by the prevalence of twomuta-
tional classes, G:CNT:A transversions and G:CNA:T transitions (Fig. 2A).se substitutions in each MAP CRC. b) Comparison of average values of transitions and
E. Each class of mutation in MAP CRC was statistically significant different from MSS and
43A. Viel et al. / EBioMedicine 20 (2017) 39–49By comparison withMSS andMSI CSCs, there was a significant overrep-
resentation of G:CNT:A in MAP CRC, with all the other mutational clas-
ses occurring at decreased frequencies (Fig. 2B). The transversionswere
equally distributed between coding and non-coding strands (1.01
ratio). Taken together, these findings are fully consistent withmutation
induction by persistent DNA 8-oxoG:A mismatches resulting from the
MUTYH defect.
3.2. Fingerprint of Base Substitutions in MAP CRCs
To identify the mutational signature associated with persistent 8-
oxoG:A mispairs, we performed a refined classification of baseFig. 3. Fingerprints of transitions and transversions inMAPCRCs.Mutational signatures are defin
and 3′ to the mutated base. The mutation types are on the horizontal axes, whereas vertical axsubstitutions to include the 3′ and 5′ flanking bases at the mutated
site (Alexandrov et al., 2013a,b). This identified a strongly conserved
MAP signature, mostly characterized by biases among the possible posi-
tions of CNA and CNT base substitutions (substitutions in mutational
signatures are referred to by the pyrimidine of the mutated Watson–
Crick base pair; Fig. 3). It is noteworthy that identical SNVs distributions
occurred in tumours from the distal and proximal colon of MAP796 pa-
tient (T1 and T2 in the sigmoid and caecum, respectively) indicating
that these tumours have a common molecular origin (Fig. 3).
To determine whether the mutational profiles of MAP CRCs differed
from those observed in CSCs we applied principal component analysis
(PCA). This revealed a perfect separation between the signatures ofed by the substitution class (in different colours) and the sequence context immediately 5′
es show the recurrence of mutations occurring in the specific sequence context.
44 A. Viel et al. / EBioMedicine 20 (2017) 39–49MAP and CSCs (Fig. 4A and Table S2). The signatures endowed with
the greater discriminant power for this separation were CNA
transversions at 5′-TCT-3′, 5′-TCA-3′ and, to a lower extent, 5′-
GCA-3′, 5′-CCA-3′, 5′-TCC-3′, 5′-GCT-3′ and 5′-CCT-3′ trinucleotides
(Fig. 4B). All these signatures identify sequences where the
damaged base (8-oxoG) is assumed to be the complementary
guanine in the C:G pair.
Trinucleotide signatures fromMAPCRCs andCSCswere compared to
a catalogue of known mutational signatures identified from N12,000
samples derived from 40 types of human cancer (Alexandrov et al.,
2013a,b). The frequently observed Signatures 1 and 5were also present
in MAP and CSCs (Fig. 4C and D) (Alexandrov et al., 2013a). In addition,
fingerprints associated with MMR-defective CSCs corresponded to sig-
natures 6, 15 and 26 that are typical of MSI tumours and a signature of
unknown origin, Signature 17, was also present in three CSCs. MAP
CRCs were characterized by a novel signature, termed Signature 36,
which is almost exclusively defined by the specific locations of
G:CNT:A transversions (Fig. 4C and D). Signature 36 identifies the loca-
tion at which mutations arise because of unrepaired 8-oxoG:A mispairs
and is essentially identical (correlation 0.98) to that reported for
germline mutations occurring in Mutyh/Ogg1/Mth1 triple knock-out
mice (Ohno et al., 2014) (Fig. 4D). This suggests that the unique spec-
trum of mutations in MAP tumours mainly reflects MUTYH loss and
the sequence specificity of DNA 8-oxoG formation.a
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with MAP CRC
It has been proposed that carcinogenesis in MUTYH-associated
polyposis follows a distinct genetic pathway (Lipton et al., 2003). Recur-
rently mutated genes in 7 MAP CRCs were identified using MuTect and
manual curation (Fig. 5A). These included APC, KRAS, PIK3CA, FAT4, TP53,
FAT1, AMER1 (or WTX), KDM6A, SMAD4 and SMAD2 (a more complete
list of genes and detailed mutation analysis are reported in Tables S3
and S4). Targeted exome sequencing of 10 additional MAP CRCs
(Table S5) confirmed the MAP-related mutagenic profiles of these 10
genes (Fig. 5B).
To examine whether these mutations were present at the adeno-
ma stage, targeted sequencing was performed in 26 MAP adenomas
(Fig. 5C and Table S5). AMER1 and APC were equally mutated in ad-
enomas and CRCs consistent with early occurrence and confirming
their role as driver genes in MAP (Rashid et al., 2016). In contrast
SMAD2, SMAD4 and TP53 were rarely mutated in adenomas indicat-
ing that they represent late events in colorectal carcinogenesis.
It was not possible to assign early or late occurrence to the other
five genes.
Comparison of MAP mutations to 376 MMR-proficient and
-deficient CRCs in COSMIC identified three different patterns of puta-
tive driver mutations (Fig. 5D). KRAS, SMAD4, SMAD2 and KDM6AAC
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45A. Viel et al. / EBioMedicine 20 (2017) 39–49were preferentially mutated in MAP compared to MSS and MSI CRCs.
A second group of genes (FAT4, FAT1 AMER1 and PIK3CA) were mu-
tated at similar frequencies in MAP andMSI CRCs. APC and TP53 com-
prised a third group that was equally mutated in all CRCs.
Thus, alterations inMAP CRCs affect thewell-establishedWNT, TGFβ,
PI3K, RAS and p53 signalling pathways (Cancer Genome Atlas Network,
2012). The mutational profiles also reveal the specificity of MAP onco-
genesis, with limited features in common with MMR-proficient and
-deficient CRC.
3.4. Mutational Signature in Oncogenes/Tumour Suppressors
The identified trinucleotide mutational signature for G:CNT:A
transversions was also present in recognized target genes for MAP
(Al-Tassan et al., 2002; Jones et al., 2002, 2004). An excess of G:CNT:A
transversions in APC leading to protein truncation has been reported
(Al-Tassan et al., 2002; Sieber et al., 2003; Jones et al., 2002). Besides
confirming this observation (G:CNT:A were 23/32, N70% of the identi-
fied APC variants), we noticed that these transversions occurred almostFA
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MAP CRCs (red), and MSS (blue) and MSI (purple) CRCs (data from a database of 376 samplesexclusively in the identified “hot-spots” for 8-oxoG (Table 1). Similarly
the majority of SNV in the AMER1 driver gene were also G:CNT:A
transversions (14/24, 58% of total mutations) in the first base of GAG
and GAA codons that lead to the formation of TAG and TAA stop codons.
Analysis of the 5′ and 3′ flanking bases at the mutated site confirmed
that thesemutations are alsowithin the recognized trinucleotide signa-
ture (i.e. Signature 36) for 8-oxoG (Table 1).
Missense G:CNT:A transversions were also preferentially located in
identified “hot-spots” of DNA oxidation in other key genes for MAP
(PIK3CA, SMAD4 and SMAD2) (Table S6). This was true even if the fre-
quency of the transversions was lower than expected (35–20% in
TP53, FAT1, FAT4) (Table S7).
KRASmutations in MAP CRCs exhibited a distinctive pattern of mu-
tations. They were exclusively G:CNT:A transversions at the 1st G of
codon 12 (GGTNTGT, nt 34) to generate a MAP-specific G12C variant
(Jones et al., 2002, 2004; Venesio et al., 2013). This is in contrast to spo-
radic CRCs in which G:CNT:A transversions predominantly affect the
2nd G of the same codon (GGTNGTT, nt 35) leading to the G12V variant
(Fig. 6A) (Cox et al., 2014). Indeed G preceded by a T in 5′-TG*G-3′ is aTP
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46 A. Viel et al. / EBioMedicine 20 (2017) 39–49mutational “hot-spot” in MAP CRCs, whereas G preceded by G in 5′-
GG*T-3′ is a “cold-spot” (Fig. 6B). To examine whether this mutational
bias reflected the sequence dependence of DNA 8-oxoG formation or
the particularly efficient processing of 8-oxoG at nt 34 by active
MUTYH, we examined the activity of purifiedMUTYH on duplexes con-
taining a single 8-oxoG:A basepair located at nt 34 or at nt 35 of the
KRAS sequence (Fig. 6A). We did not observe any difference in MUTYH
processing of these two substrates (Fig. 6B,C) and we conclude that
the overrepresentation of the G12C mutations in MAP CRC reflects the
particular susceptibility of G34 to oxidation. Thus, the different proba-
bilities of ROS-mediated guanine oxidation are likely to be a significant
determinant in the mutational signature in MAP CRCs.4. Discussion
Our analysis of cancer-related mutations associated withMUTYH in-
activation in MAP reveals that the absence of MUTYH-mediated pro-
cessing of 8-oxoG:A mispairs results in a relatively modest mutator
phenotype. The increase in mutation rates in MAP CRC is similar to
that in lymphoblastoid cell lines established from MAP patients (1.5-
to 4.0-fold) (Ruggieri et al., 2013; Grasso et al., 2014). It therefore ap-
pears that even a small increase in mutation rate due to impaired repair
of pre-mutagenic oxidative DNA lesions is an important risk factor for
cancer. CRC is the main cancer in MAP. It occurs with a relatively early
age of onset (47 years in ourMAP cases) and a lifetime risk approaching
100% (Nielsen et al., 2010). It is noteworthy that MUTYH-defective cells
are hypermutable by oxidants, indicating that the mild mutator pheno-
type can be significantly enhanced under oxidative stress conditions
(Ruggieri et al., 2013; Grasso et al., 2014). Recently a correlation has
been drawn between the lifetime risk of cancer and the total number
of cell divisions in a given tissue (Tomasetti and Vogelstein, 2015).
Based on the present observationswe propose that a combination of en-
dogenous and exogenous oxidation sources (environmental factors)
and lack of DNA repair (inherited predisposition) acting on a highlyTable 1
Location of G:CNT:A transversions in the APC and AMER1 genes.aself-renewing tissue are the main determinants of the increased MAP
cancer susceptibility.
Detailed analysis of MAP CRC mutations revealed a substantial in-
crease in a single class of base substitutions, G:CNT:A transversions.
This is in accordance with the expected persistence of DNA 8-oxoG:A
mismatches, the preferred MUTYH substrate. MUTYH also removes 2-
hydroxyadenine from 2-hydroxyadenine: G mispairs (Ohtsubo et al.,
2015). If unrepaired, these generate A:TNC:G transversions (Satou et
al., 2007). We did not observe increase in this class of mutations in
MAP CRCs and it appears that oxidation of DNA adenine is most likely
a relatively infrequent occurrence. Mutations associated with the
miscoding properties of DNA 8-oxoG are therefore the hallmark of
MUTYH inactivation.
The MAP CRC G:CNT:A transversions were equally distributed in
the transcribed and non-transcribed strands. This is at variance
with the strong bias towards higher rates of G:CNT:A transversions
located in the non-transcribed strand in cutaneous squamous cell
carcinoma and UV-irradiated normal human skin (Martincorena et al.,
2015). The lack of transcriptional strand bias is a strong indicator that
8-oxoG:A mismatches are not processed by transcription-coupled BER
in the colon.
More importantly, analysis of the sequence context of the G:CNT:A
transversions identified a specific mutational signature due to
unrepaired DNA 8-oxoG (Signature 36). It is particularly significant
that Signature 36 is almost identical to the signature of spontaneous
mutations in Ogg1−/−, Mutyh−/−, Mth1−/− mice in which all known
repair systems for DNA 8-oxoG are disabled (Ohno et al., 2014). These
coincident signatures indicate that MUTYH plays the leading role in
protecting the human genome against mutations induced by DNA
8-oxoG.
The types and location of mutations in oncogene/tumour suppressor
genes also implicate DNA 8-oxoG in MAP CRC development. KRAS
activation provides the best example of this. 100% of KRASmutations are
codon 12 G:CNT:A transversions that correspond to the acknowledged
preferential oxidation of 5′-G of GG and GGG sequences under oxidative
Fig. 6. KRAS sequence context and MUTYH adenine glycosylase activity. a) Duplex oligonucleotides containing a single 8-oxoG:A mispair at nt 34 or 35 of the KRAS sequence which are
responsible for the G12C and G12V variants in MAP (top) and sporadic CRC (bottom). Codon 12 is in bold and trinucleotides containing 8-oxoG (G*) are underlined. b) Base
substitution frequency of CNA transversions in MAP CRC. The black and red bars represent the GG*T “cold-spot” and TG*G “hot-spot” trinucleotides, respectively. c) Representative gels
of single-turnover MUTYH assays using duplexes shown in panel A. DNA glycosylase activity of humanMUTYH on single 8-oxoG:Amispairs was assayed using 10 nM duplex substrates
and 20 nM active protein. Reaction products are indicated by an arrow. Lanes 1–9: 0, 0.5, 1, 2, 3, 4, 5, 10 and 20 min. d) Plots of MUTYH glycosylase assay data under single-turnover
conditions. Data were derived from image analysis of gels by Image J and Kaleidagraph softwares. Values are the average from two independent experiments. G12C sequence (full black
circle); G12 V (empty blue circle).
47A. Viel et al. / EBioMedicine 20 (2017) 39–49stress conditions (Kawanishi et al., 2001). This sequence preference gives
rise to the G12C variant that predominates in MAP CRC rather than the
G12D or G12 V mutations that are common in sporadic CRCs (Cox et al.,
2014). It is noteworthy that G12C is the most frequent KRASmutation in
non-small-cell lung cancers in which an excess of G:CNT:A transversions
may be the result of oxidative DNA damage associated with exposure to
tobacco smoke (Govindan et al., 2012).
Mutations in other “driver” genes of colorectal carcinogenesis such
as APC and AMER1 also showed the 8-oxoG-dependent sequence con-
text specificity. In this case mutations occurred mainly at AGA and
TGA sites. Thus similarly to the 5′-GG-3′ KRAS hot-spot, the G in GA di-
nucleotides is also easily oxidized. The preferential oxidation of G in GA
or GG is consistent with a reduced ionization potential of these purine
dinucleotides. Base type, orientation and stacking interaction of consec-
utive bases are the main determinants of the ionization potential
(Sugiyama and Saito, 1996). The majority of mutations in both APC
and AMER1were G:C N T:A transversions generating stop codons. Inter-
estingly the relatively rare AMER1 mutations in sporadic CRC (10%)
show a wider spectrum of molecular changes including stop gain, mis-
sense, and synonymous variants (Sanz-Pamplona et al., 2015). Our
data suggest that the accumulation of sequence specific 8-oxoG:A
mispairs due toMUTYH inactivation is the cause of the increased muta-
bility of this gene and the strong drift towards stop codon formation.
The observation that a specific 8-oxoG mutational fingerprint increases
the probability of mutating specific oncogenes/tumour suppressors is a
rule confirmed in several examples (such as PIK3CA, SMAD4, SMAD2,
TP53, FAT4 and FAT1). Although the pathways involved in MAP CRC
are the WNT, TGFβ, PI3K, RAS and p53 signalling pathways (Cancer
Genome Atlas Network, 2012), which are commonly mutated in spo-
radic CRC, the MUTYH defect directs oncogenesis towards specific
genes that are mutated less frequently in sporadic CRCs. In this sensethe consequence of MUTYH inactivation resembles that of MMR loss.
In both cases mutation of oncogenes/tumour suppressors is driven
by the mutator phenotype that affects sequence specific structural
elements, although with clearly different molecular outcomes
(transversions versus frame-shift mutations).
The accumulation of mutations in DNA coding regions of MAP CRCs
might translate into an excess of neoepitopes able to trigger an anti-tu-
mour immune response. Similarly to the MMR-defective cancers, the
high antigenic potential of these tumours could be associated with the
improved clinical outcome reported for MAP patients (Nielsen et al.,
2010). Therefore, it would be interesting to explore if themissense mu-
tations we have identified in the target genes might have immunogenic
properties.
In conclusion, by exomic sequencing of CRCs fromMAP patients we
have identified a novel mutational signature (Signature 36) that results
from the failure to repair a specific product of DNA oxidation and is as-
sociated with an increased risk of cancer. It is remarkable that theMAP-
specific Signature 36 has never been identified in sporadic CRC. This
suggests that mutations due to unrepaired DNA 8-oxoG:A mispairs are
confined to MAP CRCs. We note, however, that Signature 36 closely re-
sembles Signature 18 (Pearson correlation coefficient of 0.77) that is
particularly prevalent in neuroblastoma in which it comprises N50% of
mutations (Fig. S2). Signature 18 has also been found at lower levels
in pancreas, breast, and gastric cancers. It is possible therefore that oxi-
dative DNAdamage also contributes to cancer aetiology in these organs.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2017.04.022.
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